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Abstract
Background: Formation of advanced glycation endproducts (AGEs), endothelial dysfunction, and low-grade inflammation
are intermediate pathways of hyperglycemia-induced vascular complications. We investigated the effect of benfotiamine on
markers of these pathways in patients with type 2 diabetes and nephropathy.
Methods: Patients with type 2 diabetes and urinary albumin excretion in the high-normal and microalbuminuric range (15–
300 mg/24h) were randomized to receive benfotiamine (n= 39) or placebo (n= 43). Plasma and urinary AGEs (Ne-
(carboxymethyl) lysine [CML], Ne-(Carboxyethyl) lysine [CEL], and 5-hydro-5-methylimidazolone [MG-H1]) and plasma
markers of endothelial dysfunction (soluble vascular cell adhesion molecule-1 [sVCAM-1], soluble intercellular adhesion
molecule-1 [sICAM-1], soluble E-selectin) and low-grade inflammation (high-sensitivity C-reactive protein [hs-CRP], serum
amyloid-A [SAA], myeloperoxidase [MPO]) were measured at baseline and after 6 and 12 weeks.
Results: Compared to placebo, benfotiamine did not result in significant reductions in plasma or urinary AGEs or plasma
markers of endothelial dysfunction and low-grade inflammation.
Conclusions: Benfotiamine for 12 weeks did not significantly affect intermediate pathways of hyperglycemia-induced
vascular complications.
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Introduction
Diabetic nephropathy (DN) is a serious complication of diabetes
and a leading cause of end-stage renal disease [1]. Thiamine and
benfotiamine, a lipophilic thiamine-derivative, have been suggest-
ed as novel therapies for diabetic complications, including DN [2].
These agents would not exert their beneficial effects by improve-
ment of hyperglycemia itself, but rather by activation of
transketolase [2,3]. This leads to a decrease in triosephospates
and methylglyoxal; i.e. the major precursors of advanced glycation
endproducts (AGEs), and subsequently inhibition of endothelial
dysfunction and chronic low-grade inflammation [4,5]. However,
in a recent 12-week double-blind placebo-controlled trial in
patients with type 2 diabetes, we found no effect of benfotiamine
on urinary albumin excretion (UAE) or renal tubular damage
markers [6]. One possibility is that our choice for these primary
endpoints is too late in the sequence of events, because even the
reduction in AGEs that occurs after pancreas transplantation has
been reported to take years to translate into an effect on urinary
albumin excretion [7]. We now aimed to evaluate the effect of
benfotiamine on AGEs and markers of endothelial dysfunction
and chronic low-grade inflammation, and to find ground to set up
a study of longer duration.
Methods
Patients and study design
A detailed description of the study has been published [6]. The
protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Protocol S1 and Check-
list S1. We included patients from the outpatients department in
the Isala Clinics, Zwolle, the Netherlands, in the period from
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January 2008 till June 2009. Included subjects were patients with
type 2 diabetes, aged 40 to 75 years, with UAE between 15–
300 mg/24h despite treatment with ACE inhibitors (ACE-Is) and/
or angiotensin receptor blockers (ARBs). Patients (n=86) were
randomized to receive either benfotiamine (Wo¨rwag pharma,
Bo¨blingen, Germany) 300 mg t.i.d. (total daily dose 900 mg) or
placebo during 12 weeks. On each visit (baseline, 6 weeks, and
12 weeks), patients delivered 24-h urine collection, and additional
morning spot-urine and blood samples were taken. All patients
signed informed consent. This trial was conducted in accordance
with the Helsinki Declaration and approved by the Medical Ethics
Committee of the Isala Clinics, Zwolle, the Netherlands.
Clinical laboratory investigations
For the current report, urine and plasma samples were stored
frozen at 280uC until assessment. Detection of plasma AGEs Ne-
(carboxymethyl) lysine (CML), Ne-(Carboxyethyl) lysine (CEL) and
urine AGEs (CML, CEL and the methylglyoxal-arginine-adduct
5-hydro-5-methylimidazolone (MG-H1)) in 24-h urine samples
was performed by means of a stable-isotope-dilution tandem mass
spectrometry method [8,9]. Soluble vascular cell adhesion
molecule-1 (sVCAM-1), soluble intercellular adhesion molecule-1
(sICAM-1), high sensitivity C-reactive protein (hs-CRP) and serum
amyloid-A (SAA) were assessed by multi-array detection system
(SECTOR-Imager 2400, Mesoscale Discovery, Maryland). Solu-
ble E-selectin and myeloperoxidase (MPO) were measured by
commercially available multiplex assays (Millipore, Massachu-
setts). Other measurements were performed according to standard
hospital procedures.
Statistical analysis
Variables with a normal distribution are presented as mean and
standard deviation and variables with a skewed distribution are
presented as median and interquartile range. Intention-to-treat
analysis and per-protocol analysis were planned. After randomi-
zation, four patients from the benfotiamine group withdrew from
consent. Therefore, these subjects were not available for follow-up
visits and no samples could be obtained from these subjects. All
remaining patients (39 patients in the benfotiamine group and 43
patients in the placebo group) were available for analyses. In per-
protocol analyses, patients who deviated from the study protocol
(non-compliance or change in concomitant medications, n=1 in
the benfotiamine group and n=3 in the placebo group [6]) were
excluded. In the previous report [6], analyses of the primary
endpoints (UAE and KIM-1) were presented. In this report, we
present predefined analyses of secondary endpoints: plasma and
urinary AGEs and plasma levels of biomarkers of endothelial
dysfunction and low-grade inflammation. Using ANOVA for
repeated measures (Mixed Model Analysis), within-subjects factors
(effect of time; disease modifying model), effects of the between-
subjects factors (difference between groups; symptomatic relief),
and interaction between time of visit (0, 6, and 12 weeks) and
group (benfotiamine versus placebo) were evaluated. Q-Q plots
were used to assess whether the residuals of the dependent
variables in the model had normal distribution. Because of skewed
distribution of the residuals, logarithmic transformation (natural
logarithm) of the data was performed before analysis. The results
are summarized in terms of estimated means with 95% confidence
intervals (CI). Differences in mean change between benfotiamine
and placebo at 6 weeks and 12 weeks are presented as mean
difference with 95% CI. P-values for time, group, and time*group
interaction are presented. A two-sided P-value ,0.05 was
considered statistically significant. Statistics were done with SPSS,
version 16.0 (Chicago, IL).
Results
A flow diagram of the trial is shown in figure 1. Baseline
characteristics are presented in table 1. At baseline, blood
thiamine was correlated with urinary excretion of CML
(r=0.26, P=0.02) and CEL (r=0.25, P=0.02). No significant
correlations of thiamine status with other AGEs or biomarkers of
endothelial dysfunction and low-grade inflammation were found.
Baseline characteristics were not materially different between
groups, except for a more frequent use of oral hypoglycaemic
agents and a slightly higher plasma creatinine in the placebo
group. As shown in table 2, benfotiamine treatment had neither a
significant effect on plasma or urinary AGEs nor on markers of
endothelial dysfunction or chronic low-grade inflammation.
Adjustment for baseline differences gave similar results. Results
of per-protocol analysis (not shown) were not different from
presented intention-to-treat analyses. Subgroup analyses in
patients with low range UAE (,100 mg/24u) and high range
UAE (.100 mg/24h) did not reveal differences in response to
benfotiamine compared to placebo.
Discussion
We found that 12-week treatment with benfotiamine in patients
with type 2 diabetes did not result in a decrease of plasma AGEs,
urinary excretion of AGEs, plasma biomarkers of endothelial
Figure 1. CONSORT flow diagram of the study.
doi:10.1371/journal.pone.0040427.g001
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dysfunction or plasma biomarkers of chronic low-grade inflam-
mation.
Benfotiamine is converted to thiamine pyrophosphate, a co-
factor of transketolase. The activation of transketolase plays a
crucial role in oxidative and non-oxidative pentosephosphate
pathways that inhibit vascular complications of diabetes [3,10]. In
our trial, although we found that benfotiamine resulted in a
significant improvement in thiamine status (a significant increase
in thiamine levels and transketolase activity), there was no
significant difference between the benfotiamine group and the
placebo group regarding urinary albumin excretion, urinary
excretion of tubular damage markers, or blood pressure [6].
Studies in diabetic animals have shown that benfotiamine
inhibited protein kinase C, formation of AGEs and oxidative
stress, indicating a protective effect against hyperglycemia-induced
endothelial dysfunction and inflammation [2,4].
To the best of our knowledge, our study is the first randomised
controlled trial that has investigated the effect of benfotiamine on
AGEs formation and markers of low-grade inflammation in
humans. Results from previous studies on thiamine and benfotia-
mine on endothelial function in humans are conflicting. An earlier
cross-sectional analysis in 74 patients with type 1 and type 2
diabetes found an inverse association of thiamine status with
sVCAM-1 [11], suggesting an effect of thiamine status on markers
of endothelial dysfunction. However, in a study in patients with
type 2 diabetes [5], the same group found no effect of thiamine
supplementation on sVCAM-1, We also did not find an effect of
benfotiamine on markers of endothelial dysfunction, including
sVCAM-1. Nevertheless, in a study in 13 patients with type 2
diabetes [12], beneficial effects of benfotiamine (1050 mg/day) on
the endothelial damage and oxidative stress that occurs after
consumption of an AGE-rich meal were suggested to be already
present after three days of treatment. While on the basis of this
experiment longer periods of treatment with benfotiamine
(12 weeks in our study) might be anticipated to be sufficient to
cause an effect on formation of AGEs and endothelial damage, the
effects of benfotiamine could also be more directly meal-related
rather than affecting steady-state concentrations.





Males (n (%)) 30 (77%) 33 (82%)
Age (years) 65.3 6 5.9 64.6 6 6.1
BMI (kg/m2) 32.1 6 5.1 31.9 6 5.9
Duration of diabetes (years) 12 [9; 18] 10 [7; 18]
SBP (mmHg) 140 6 16 137 6 20
DBP (mmHg) 67 6 8 76 6 10
A1c (%) 7.3 6 0.9 7.4 6 0.9
Plasma creatinine (mmol/l) 84 6 19 87 6 23
UAE (mg/24h) 90 [38; 267] 97 [48; 177]
Thiamine (nmol/l) 126 6 23 122 6 23
Plasma AGEs
CML (nmol/mmol lysine) 64.48 [58.21; 69.69] 62.51 [54.88; 71.20]
CEL (nmol/mmol lysine) 51.14 [44.78; 59.25] 56.99 [43.71; 62.10]
Urine AGEs
CML excretion (nmol/24h) 7630 [6761; 10576] 8879 [6476; 11769]
CML/creatinine (nmol/mmol) 572 [416; 731] 596 [483; 788]
CEL excretion (nmol/24h) 12405 [9105; 15240] 11204 [8922; 16384]
CEL/creatinine (nmol/mmol) 763 [602; 1061] 871 [648; 1034]
MG-H1 excretion (nmol/24h) 479122 [34431; 69775] 44930 [32095; 58614]
MG-H1/creatinine (nmol/mmol) 3459 [2196; 4856] 2999 [2260; 4563]
Endothelial dysfunction markers
s-ICAM (ng/ml) 257.3 [222.0; 281.1] 241.7 [213.2; 308.0]
s-VCAM (ng/ml) 399.1 [362.7; 431.7] 388.3 [335.8; 461.9]
s-E-Selectin (ng/ml) 45.3 [29.8; 54.6] 39.5 [26.8; 51.3]
Low-grade inflammation markers
Hs-CRP (ng/ml) 1395 [754; 2891] 1738 [824; 4097]
SAA (ng/ml) 1356 [927; 2028] 1162 [694; 2328]
MPO (ng/ml) 20.4 [9.9; 28.3] 20.4 [6.2; 27.2]
Data are mean 6 standard deviation or median [interquartile range].
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; A1c, Glycated haemoglobin; UAE, urinary albumin excretion; AGEs, advanced glycation
endproducts; CML, Ne-(Carboxymethyl) lysine; CEL, Ne-(Carboxyethyl) lysine; MG-H1, 5-hydro-5-methylimidazolone; s-ICAM, serum inter-cellular adhesion molecule-1; s-
VCAM, serum vascular cell adhesion molecule-1; Hs-CRP, high sensitive C-reactive protein; SAA, serum amyloid A; MPO, myeloperoxidase.
doi:10.1371/journal.pone.0040427.t001
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Table 2. Estimated means of the log-transformed data at each visit, changes within group compared to baseline, and mean







Time Group Time x Group
Plasma AGEs
CML (nmol/mmol lysine)
Baseline 4.17 (4.11 to 4.23) 4.15 (4.09 to 4.20)
Week 6 4.15 (4.09 to 4.21) 4.14 (4.09 to 4.20)
Week 12 4.15 (4.09 to 4.21) 4.12 (4.07 to 4.18)
At 6 weeks 20.02 (20.12 to 0.08) 0.00 (20.10 to 0.09) 20.01 (20.13 to 0.10)
At 12 weeks 20.02 (20.12 to 0.08) 20.02 (20.12 to 0.07) 0.01 (20.11 to 0.12) 0.77 0.50 0.95
CEL (nmol/mmol lysine)
Baseline 3.94 (3.86 to 4.02) 3.97 (3.90 to 4.05)
Week 6 3.88 (3.81 to 3.96) 3.94 (3.87 to 4.01)
Week 12 3.90 (3.83 to 3.97) 3.98 (3.92 to 4.04)
At 6 weeks 20.06 (20.18 to 0.07) 20.03 (20.16 to 0.09) 20.02 (20.17 to 0.12)
At 12 weeks 20.04 (20.17 to 0.08) 0.01 (20.11 to 0.13) 20.05 (20.19 to 0.09) 0.45 0.06 0.78
Urine AGEs
U-CML excretion (nmol/24h)
Baseline 8.98 (8.83 to 9.13) 9.08 (8.93 to 9.22)
Week 6 8.99 (8.85 to 9.13) 9.08 (8.94 to 9.21)
Week 12 9.04 (8.91 to 9.17) 9.02 (8.90 to 9.15)
At 6 weeks 0.01 (20.23 to 0.26) 0.00 (20.23 to 0.24) 0.01 (20.27 to 0.29)
At 12 weeks 0.06 (20.18 to 0.30) 20.05 (20.27 to 0.17) 0.11 (20.16 to 0.38) 0.99 0.31 0.67
U-CML/creatinine (nmol/mmol)
Baseline 6.29 (6.14 to 6.44) 6.40 (6.26 to 6.55)
Week 6 6.30 (6.16 to 6.45) 6.31 (6.17 to 6.44)
Week 12 6.30 (6.13 to 6.47) 6.38 (6.22 to 6.54)
At 6 weeks 0.01 (20.24 to 0.27) 20.10 (20.34 to 0.15) 0.11 (20.18 to 0.40)
At 12 weeks 0.01 (20.27 to 0.29) 20.02 (20.28 to 0.24) 0.03 (20.28 to 0.34) 0.82 0.29 0.74
U-CEL excretion (nmol/24h)
Baseline 8.98 (8.83 to 9.13) 9.08 (8.93 to 9.22)
Week 6 8.99 (8.85 to 9.13) 9.08 (8.94 to 9.21)
Week 12 9.04 (8.91 to 9.17) 9.02 (8.90 to 9.15)
At 6 weeks 0.01 (20.23 to 0.26) 0.00 (20.23 to 0.24) 0.01 (20.27 to 0.29)
At 12 weeks 0.06 (20.18 to 0.30) 20.05 (20.28 to 0.18) 0.11 (20.16 to 0.38) 0.99 0.31 0.67
U-CEL/creatinine (nmol/mmol)
Baseline 6.29 (6.14 to 6.44) 6.40 (6.26 to 6.55)
Week 6 6.30 (6.16 to 6.45) 6.31 (6.17 to 6.44)
Week 12 6.30 (6.13 to 6.47) 6.38 (6.22 to 6.54)
At 6 weeks 0.01 (20.24 to 0.27) 20.10 (20.34 to 0.15) 0.11 (20.18 to 0.40)
At 12 weeks 0.01 (20.27 to 0.29) 20.02 (20.28 to 0.24) 0.03 (20.28 to 0.35) 0.82 0.29 0.74
MG-H1 excretion (nmol/24h)
Baseline 10.74 (10.56 to 10.91) 10.72 (10.55 to 10.89)
Week 6 10.63 (10.46 to 10.80) 10.72 (10.55 to 10.88)
Week 12 10.63 (10.46 to 10.81) 10.58 (10.42 to 10.75)
At 6 weeks 20.10 (20.40 to 0.19) 0.00 (20.28 to 0.28) 20.10 (20.44 to 0.24)
At 12 weeks 20.10 (20.40 to 0.20) 20.14 (20.42 to 0.15) 0.04 (20.30 to 0.38) 0.38 0.94 0.69
U-MG-H1/creatinine
(nmol/mmol)
Baseline 8.05 (7.85 to 8.24) 8.05 (7.86 to 8.23)
Week 6 7.94 (7.75 to 8.13) 7.94 (7.78 to 8.14)
Benfotiamine and Diabetic Complications
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Compared to previous studies in animals [2] and humans
[5,13], a daily dose of 900 mg is considered as a high dose. Due to
its pharmacokinetics, benfotiamine is absorbed considerably better
than thiamine. However, it is important to realize that intestinal
and renal tubular transport of thiamine is tightly regulated to








Time Group Time x Group
Week 12 7.90 (7.72 to 8.08) 7.90 (7.77 to 8.11)
At 6 weeks 20.10 (20.44 to 0.23) 20.08 (20.40 to 0.23) 20.02 (20.40 to 0.36)
At 12 weeks 20.15 (20.47 to 0.17) 20.11 (20.41 to 0.20) 20.04 (20.41 to 0.33) 0.36 0.80 0.98
Endothelial dysfunction markers
s-ICAM (ng/ml)
Baseline 5.53 (5.44 to 5.61) 5.55 (5.47 to 5.63)
Week 6 5.55 (5.47 to 5.64) 5.53 (5.45 to 5.62)
Week 12 5.56 (5.48 to 5.63) 5.52 (5.44 to 5.59)
At 6 weeks 0.03 (20.12 to 0.18) 20.02 (20.16 to 0.12) 0.05 (20.12 to 0.22)
At 12 weeks 0.03 (20.11 to 0.17) 20.03 (20.17 to 0.10) 0.06 (20.10 to 0.22) 0.99 0.74 0.74
s-VCAM (ng/ml)
Baseline 5.98 (5.92 to 6.05) 5.98 (5.92 to 6.04)
Week 6 5.99 (5.93 to 6.05) 5.96 (5.90 to 6.02)
Week 12 6.02 (5.96 to 6.09) 5.96 (5.89 to 6.02)
At 6 weeks 0.01 (20.10 to 0.11) 20.02 (20.12 to 0.09) 0.02 (20.10 to 0.14)
At 12 weeks 0.04 (20.07 to 0.15) 20.02 (20.12 to 0.08) 0.06 (20.07 to 0.18) 0.91 0.19 0.64
s-E-selectin (ng/ml)
Baseline 3.66 (3.46 to 3.85) 3.57 (3.39 to 3.75)
Week 6 3.84 (3.70 to 3.97) 3.71 (3.59 to 3.84)
Week 12 3.79 (3.64 to 3.95) 3.69 (3.54 to 3.84)
At 6 weeks 0.18 (20.10 to 0.46) 0.14 (20.13 to 0.41) 0.04 (20.28 to 0.37)
At 12 weeks 0.14 (20.16 to 0.44) 0.12 (20.17 to 0.40) 0.02 (20.32 to 0.36) 0.14 0.10 0.96
Low-grade inflammation markers
Hs-CRP (ng/ml)
Baseline 7.49 (7.13 to 7.85) 7.56 (7.21 to 7.91)
Week 6 7.63 (7.28 to 7.98) 7.41 (7.07 to 7.75)
Week 12 7.54 (7.20 to 7.87) 7.51 (7.19 to 7.83)
At 6 weeks 0.14 (20.48 to 0.75) 20.15 (20.74 to 0.44) 0.29 (20.41 to 0.98)
At 12 weeks 0.05 (20.55 to 0.64) 20.05 (20.63 to 0.52) 0.10 (20.59 to 0.78) 0.99 0.67 0.71
SAA (ng/ml)
Baseline 7.26 (6.95 to 7.58) 7.22 (6.92 to 7.53)
Week 6 7.29 (6.96 to7.61) 7.07 (6.76 to 7.38)
Week 12 7.14 (6.83 to 7.46) 7.20 (6.90 to 7.50)
At 6 weeks 0.02 (20.53 to 0.57) 20.15 (20.68 to 0.37) 0.18 (20.45 to 0.81)
At 12 weeks 20.12 (20.66 to 0.42) 20.02 (20.54 to 0.50) 20.10 (20.72 to 0.51) 0.88 0.60 0.67
MPO (ng/ml)
Baseline 2.90 (2.61 to 3.20) 2.80 (2.51 to 3.09)
Week 6 2.89 (2.61 to 3.17) 2.67 (2.40 to 2.94)
Week 12 2.88 (2.61 to 3.16) 2.72 (2.46 to 2.98)
At 6 weeks 20.02 (20.52 to 0.48) 20.13 (20.61 to 0.35) 0.11 (20.45 to 0.68)
At 12 weeks 20.02 (20.51 to 0.47) 20.08 (20.56 to 0.39) 0.06 (20.50 to 0.63) 0.87 0.15 0.92
Data are log-transformed and presented as mean (95% confidence interval) or mean difference (95% confidence interval for difference).
CML, Ne mn-(Carboxymethyl) lysine; CEL, Ne-(Carboxyethyl) lysine; MG-H1, 5-hydro-5-methylimidazolone; s-ICAM, serum inter-cellular adhesion molecule-1; s-VCAM,
serum vascular cell adhesion molecule-1; Hs-CRP, high sensitive C-reactive protein; SAA, serum amyloid A; MPO, myeloperoxidase.
doi:10.1371/journal.pone.0040427.t002
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is up-regulated in presence of deficiency states and down-regulated
in response to an excess supply of these nutrients, which may
account for a rapid excretion of thiamine in the urine after
consumption of a high dose of benfotiamine [14,15]. Additionally,
studies in experimental animals have shown that chronic kidney
disease results in down-regulation of expression of key transporters
and receptors for thiamine and folate, which can further limit the
bioavailability of these micronutrients [16]. In our study, although
higher blood thiamine levels and transketolase activity was
achieved in the benfotiamine group, thiamine levels in renal cells
might still be deficient even in case of high blood thiamine.
Our objectives were studied in a relevant study population,
including patients with type 2 diabetes and UAE in the high-
normal and microalbuminuric range treated with ACE-Is and/or
ARBs. An important limitation of this study is that AGEs and
biomarkers of endothelial dysfunction and inflammation were
measured in urine and blood. Intracellular concentrations of these
markers in target organs (e.g. glomeruli and tubuli) may give
additional information on effects of benfotiamine on vascular
complications. Therefore, assessment of intracellular AGEs in
future studies would be necessary.
In conclusion, 12-week benfotiamine treatment did neither
significantly affect plasma or urine AGEs nor plasma biomarkers
of endothelial dysfunction or chronic low-grade inflammation in
patients with type 2 diabetes and UAE in the high-normal and
microalbuminuric range. Because small short-term effects can not
be excluded and potential effects that take long to ensue can not be
studied in a 12-week study, larger or longer term studies are
necessary to elucidate whether benfotiamine reduces formation of
AGEs or diminishes the risk of hyperglycemia-induced vascular
complications.
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